References - AMD Future Perspectives: New promising drugs

1. Holz FG, Dugel PU, Weissgerber G, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology. 2016 May;123(5):1080-9.
2. Hussain RM, Ciulla TA. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Jul 31.
3. Singerman LJ WA, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Association for Research in Vision and Ophthalmology Annual Meeting; May 3-7, 2015; Denver, CO.
4. Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 2017 May 24.
5. Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval. 2017 [05/07/2017]; Available from: https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients.
6. Positive Top-Line Data Reported from Phase 2 Study for DARPin abicipar pegol in wet AMD. 2014 [10/07/2017]; Available from: https://www.molecularpartners.com/positive-top-line-data-reported-from-phase-2-study-for-darpin-abicipar-pegol-in-wet-amd/.
7. Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD. [updated 04/04/201710/07/2017]; Available from: https://clinicaltrials.gov/show/NCT02543229.
8. Opthea Reports Positive Data from wet AMD Clinical Trial 2016 [updated 26/07/2016]; Available from: http://www.opthea.com/pub/pdf/ASX_OPT_OPT302 Ph 1 Secondary Endpoints_FINAL_16 07 26_Aust.pdf.
9. Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75-83.
10. Lee M, Bikram M, Oh S, Bull DA, Kim SW. Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm Res. 2004 May;21(5):736-41.
11. Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3796-805.
12. Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012 Sep;119(9):1867-73.

13. Titze-de-Almeida R, David C, Titze-de-Almeida SS. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharm Res. 2017 Jul;34(7):1339-63.
14. Laganovska G. First-in-Human Results of a Refillable Drug delivery Implant Providing Release of Ranibizumab in Patients with Neovascular AMD. Anual Meeting AAO; 09/12/2012; Chicago, IL2012.
15. 2017 [16/07/2017]; Available from: http://www.ocutx.com/pipeline/intravitreal-depots.
16. Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases. 2016 [16/07/2017]; Available from: http://investors.ocutx.com/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2211419.
17. PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop. [cited 2016 29/06/2017]; Available from: http://www.panopticapharma.com/docs/news/Positive-Results-from-Phase-1-2-Clinical-Trial-of-PAN-90806.pdf.
18. Jaffe GJ, Eliott D, Wells JA, Prenner JL, Papp A, Patel S. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2016 Jan;123(1):78-85.
19. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005 Sep 16;97(6):512-23.
20. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010 Jan;176(1):85-97.
21. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008 May 15;22(10):1276-312.
22. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004 Feb;18(2):338-40.
23. Mitchell TS, Bradley J, Robinson GS, Shima DT, Ng YS. RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis. 2008;11(2):141-51.
24. Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration. 2016 [02/07/2017]; Available from: http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=1003651.
25. Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration. 2016 [04/07/2017]; Available from: http://www.prnewswire.com/news-releases/regeneron-announces-phase-2-study-of-aflibercept-co-formulated-with-rinucumab-anti-pdgfr-beta-shows-no-benefit-over-aflibercept-alone-in-neovascular-age-related-macular-degeneration-300337055.html.
26. T. J. A phase 1 study of oral tyrosine kinase inhibitor (X-82) in previously treated wet age-related macular degeneration. 15th EURETINA Congress; 17-20/09/2015; Nice, France2015.
27. Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014 Oct;124(10):4564-76.

28. Koss MJ, Pfister M, Koch FH. Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol. 2011;2011:459251.
29. Oshima Y, Takahashi K, Oshima S, et al. Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization. J Cell Physiol. 2004 Jun;199(3):399-411.
30. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997 Jul 04;277(5322):55-60.
31. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999 Dec 24;286(5449):2511-4.
32. Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015 Mar;122(3):545-54.
33. Papadopoulos KP, Kelley RK, Tolcher AW, et al. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15;22(6):1348-55.
34. Brown DM. Phase 1 study of combination therapy with nesvacumab and aflibercept for neovascular AMD and diabetic macular edema. AAO Annual Meeting; October 2016; Chicago, IL2016.
35. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov;8(11):1265-88.
36. P. Dugel DS, P. Cech, M. Giraudon, A. Boulay, P. Szczesny, J. Sahni. A novel anti-VEGF/anti-angiopoietin2 bispecific monoclonal antibody for wet age-related macular degeneration and diabetic macular edema. 16th EURETINA Congress; 8-11/09/20162016.
37. Cocco E, Hu Z, Richter CE, et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 2010 Sep 07;103(6):812-9.
38. Christine R. Gonzales GB. A Phase 2 Study (EMERGE) Evaluating Repeated Intravitreal Administration of ICON-1 in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). ARVO 2017; Baltimore2017.
39. Saito T, Bokhove M, Croci R, et al. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1. Cell Rep. 2017 May 30;19(9):1917-28.

View PDF